Page tree
Skip to end of metadata
Go to start of metadata

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 41 Next »

Overview of Current Notices

For additional Relevant links with regards to Content Development Information please click here Content Development Information

ItemsProposed improvement

Planned Release date

(*this is provisional only and is subject to change)

1LOINC timeline changes - please refer to Roadmap link here LOINCJuly 2018 and potentially other future releases.
2

Revision of IS A relationships for anatomy concepts 

The new anatomy concept model has implemented the new Description Logic features, e.g. reflective and transitive property, general concept axioms, for consistent logical modeling. However, the new model cannot be implemented in production because these DL features currently are not available in production. The implementation of them will depend on the enhanced logic profile for SNOMED CT which is under development by the Modeling AG. Yet, the inferred IS A relationship from the OWL anatomy ontology can be reviewed and implemented in the production. This will utilise the outcomes of the new anatomy model as well as evaluate the design of the new model. In particular, it is important to review the changes of IS-A relationships in anatomy for quality assurance and minimise impact to other hierarchies, such as disorders, procedures, observables, situations etc.

The first subject area for revision is the sub-hierarchy of skin structure. The majority changes have been made in the January 2018 release. The rest will be completed in July 2018 release.

For July 2018 release, the subject area for revision of IS A relationships will be determined and updated in the following confluence page.


July 2018 International Edition
3

Summery of Drugs changes

Groupers Chemical structure

  • Most existing concepts remodeled, with modeling and terming updated per editorial guidelines
  • Top level groupers 763760008 | Medicinal product categorized by structure (product) and 767102007 | Medicinal product categorized by chemical element (product) created; this is an incremental improvement and there may still be missing subtypes

Groupers Dispositions

  • Most existing concepts remodeled, with modeling and terming updated per editorial guidelines
  • Top level grouper 766779001| Medicinal product categorized by disposition (product) created; this is an incremental improvement and there may still be missing subtypes

Groupers Intended site

  • All existing concepts remodeled, with modeling and terming updated per editorial guidelines

Medicinal product (MP)

  • Most existing concepts remodeled (>3400), with modeling and terming updated per editorial guidelines
  • Semantic tag updated to (medicinal product)
  • Terming update to include "product" in Preferred Terms in progress but not visible in alpha release 

Medicinal product form (MPF)

  • Most existing concepts remodeled (>1300), with modeling and terming updated per editorial guidelines
  • Semantic tag updated to (medicinal product form)

Clinical drug (CD)

  • Existing concepts are in the process of being remodeled and are not ready for review at this time
  • Preview of these concepts will be made available at a later date

Pharmaceuticaldose form

  • Most existing concepts remodeled, with modeling and terming updated per editorial guidelines
  • Semantic tag updated to (dose form)

General

The Alpha Release is a snapshot of the work-in-progress authoring environment; not all concepts are in scope for review at this time. Feedback given for concepts noted as out of scope will be rejected.

For drugs:

  • Review should be limited to sufficiently defined inferred descendants of 763158003 | Medicinal product (product)
  • Primitive concepts are out of scope for review
  • Concepts with semantic tag (clinical drug) are out of scope for review
  • Concepts with semantic tag (product) and containing product strength are out of scope for review

For dose forms:

  • Review should be limited sufficiently defined inferred descendants of 736542009 | Pharmaceutical dose form (dose form)
  • Primitive concepts are out of scope for review
  • Concepts without semantic tag (dose form) are out of scope for review
  • Documentation:
  • Editorial Guide draft version for the Medicinal Product Hierarchy available for review
  • Editorial Guide draft version for the Pharmaceutical Dose Form Hierarchy available for review

Briefing

Briefing note - Use of Additional Axiom Functionality and Remodeling Product Roles.pdf

July 2018 International Edition
4Summary of Substances Changes

Top Level

  • Allergen class subhierarchy. The work to inactivate the allergen class subhierarchy has not yet started and so will not be evident in the Alpha release data. It is anticipated that the initial work on this will be evident in the July 2018 release.
  • Dietary subhierarchy. To remove context of use from the substance concepts and manage the situation where substances can be both a pharmaceutical ingredient and a foodstuff 80 substances that had a tag of “- dietary” in the Fully Specified Name (FSN) and the Preferred Term (PT) were inactivated. Replacement concepts concept without  "-dietary" in the FSN and PT were created. The top level concept "Dietary substance (substance)" has been inactivated and replaced with a new concept "Edible substance (substance)".
  • Radioactive isotope substances. These concepts have been remodelled and the terming normalised to provide consistent representation without the use of carats.
  • Cancer related substance. The subhierarchy has now been removed. Some concept have been inactivated. Some have been moved within the substances hierarchy.

Disposition groupers

  • Disposition groupers within the substance hierarchy have been modelled as fully defined concepts. The creation of the new top level substance concept of "Substance categorised by disposition" will allow these to be modelled by proximal primitive authoring.
  • Existing disposition grouper concepts in the substances hierarchy have been retained where appropriate and have been remodelled to conform to SNOMED CT Editorial policy. Examples as below.
    •  Substance with angiotensin-converting enzyme inhibitor mechanism of action (substance)
    •  Substance with beta-1 adrenergic receptor agonist mechanism of action (substance)
    •  Substance with phosphodiesterase inhibitor mechanism of action (substance)
  • Currently there are in excess of 200 disposition groupers in the substances hierarchy that have been remodelled.
  • Work to remodel existing substance disposition groupers is ongoing.
  • New concepts will be added as identified.

Role groupers

Role groupers within the substances hierarchy are being inactivated where this is possible without creating disruption in other hierarchies. At the start of this work there were approximately 600 role groupers. Currently in the region of 100 role grouper substance concepts have been inactivated or remodelled.This work is ongoing.

Many of these role grouper concepts remain in the substances hierarchy pending a solution for the roles concepts within the terminology as a whole and so will still be present in the July 2018 release.

Structural groupers

Structural groupers within the substance hierarchy have been modelled as primitive concepts.

Existing structural grouper concepts in the substances hierarchy have been retained where appropriate and have been remodelled to conform to SCT Editorial policy.

New structural grouper concepts have been added.

Groupers that identify X or derivatives where X is a specific substance will be inactivated. Some of these concepts have already been inactivated. As the implementation of the IS Modification attibute is carried out the remainder of these concepts will be inactivated.

Structural groupers that reference a chemical group will be retained.

e.g. Amides and derivatives (substance)

Where the structural group name also refers to a specific chemical the grouper has been re-termed “Substance with X structure” 

e.g. Substance with tetracycline structure (substance)

Combined groupers

Combined groupers that include a role will be inactivated where this is possible without causing disruption in other hierarchies. Inactivation of some of these concepts in the substances hierarchy is waiting on a solution for the roles concepts within the terminology as a whole and so will still be present in the July 2018 release.

Groupers of disposition + structure will be retained in the substance hierarchy. Existing concepts have been remodelled to conform to SCT Editorial policy. Examples as below.

Antimony compound with antiprotozoal mechanism of action (substance)

Quaternary ammonium compound with anticholinergic mechanism of action (substance)

Piperidine derivative with histamine receptor antagonist mechanism of action (substance)

New concepts will be added as required.

Use of the Is Modification attribute

The implementation of the IS Modification attibute has been started. This has achieved a flattening of the substance hierarchy. Priority has been given to the remodelling of substances associated with the medicinal products. This work is ongoing.

The following guidelines have been developed.

1. Substances may have zero to many Is modification attribute(s). e.g  Iodine (131-I) labelled monoclonal antibody (substance) has 2 IS MODIFICATION attribute values.

2. Salts have a IS MODIFICATION relationship to the base e.g. Doxepin hydrochloride (substance) IS MODIFICATION of Doxepin (substance)

3. Hydrates have a IS MODIFICATION relationship to the unspecified salt e.g. Caffeine hydrate (substance) IS MODIFICATION of Caffeine (substance)

4. Anhydrous salts have a IS MODIFICATION relationship to the unspecified salt e.g. Theophylline anhydrous (substance) IS MODIFICATION of Theophylline (substance)

5. Stereoisomers are subtypes of the unspecified substance. e.g.. Dextrothyroxine IS A thyroxine. 

6. There is no IS MODIFICATION relationship between stereoisomers.

Further guidelines will be added to the published documentation as they are developed.

The initial population of the IS MODIFICATION attribute is still subject to manual authoring input to ensure compliance to Editorial guidelines and so some areas of content may appear to be non-conformant in the Alpha release data.

July 2018 International Edition
5

Internal QA

Test and procedure status: Inactivated 143 concepts in the Situations and Findings hierarchies with pattern "Test/procedure OFFERED" and "Test/procedure NOT OFFERED" as these represent an administrative status.


6

Improvement to the Release package naming convention

In order to ensure that the status of each package is correctly identified, we will be capitalising the third element of the naming convention. For example therefore, instead of the January 2018 International Edition release package being called:

SnomedCT_InternationalRF2_Production_20180131T120000Z.zip

It will instead be called:

SnomedCT_InternationalRF2_PRODUCTION_20180131T120000Z.zip

Alpha/Beta releases will be called:

SnomedCT_InternationalRF2_ALPHA_20180131T120000Z.zip

SnomedCT_InternationalRF2_BETA_20180131T120000Z.zip

This should have no impact on most users, this is provided for visibility of anyone who's upload routine might be case-sensitive.

January 2018 International Edition - COMPLETE
7

Improvement to the Release file naming convention for the Asssociation Reference file

In order to improve the description of this file, we will be updating the file naming convention from:


'der2_cRefset_AssociationReferenceSnapshot_INT_*.txt'

to:

'der2_cRefset_AssociationSnapshot_INT_*.txt'

....as of the January 2018 International Edition

January 2018 International Edition - COMPLETE
  • No labels